Mesenteric Tumor Deposits in Midgut Small Intestinal Neuroendocrine Tumors Are a Stronger Indicator Than Lymph Node Metastasis for Liver Metastasis and Poor Prognosis.
Mesenteric tumor deposits (MTDs) are not included in the American Joint Committee on Cancer (AJCC) staging system for midgut small intestinal neuroendocrine tumors (NETs). We examined the prognostic significance of MTDs associated with midgut NETs. Hematoxylin and eosin slides from 132 resected jejunal/ileal NETs were reviewed for AJCC tumor stage, lymph node (LN) metastasis, MTDs, and hepatic metastases. MTDs were defined as discrete irregular mesenteric tumor nodules discontinuous from the primary tumor. Clinical or pathologic evidence of metastases and survival data were abstracted from electronic medical records. The cohort included 72 male and 60 female patients with a median age of 60 years. LN metastasis, MTDs, and liver metastasis were present in 80%, 68%, and 58% of patients, respectively. Female sex and presence of MTDs were independent predictors of liver metastasis. The odds ratio for hepatic metastasis in the presence of MTDs was 16.68 (95% confidence interval [CI], 4.66-59.73) and 0.81 (95% CI, 0.20-3.26) for LN metastasis. Age, MTDs, and hepatic metastasis were associated with disease-specific survival (DSS) in univariate analysis. Primary tumor histologic grade, pT3/T4 stage, and LN metastasis were not associated with DSS. Multivariate analysis of liver metastasis-free survival stratified by tumor grade showed that MTDs were associated with adverse outcomes. The hazard ratio for MTDs was 4.58 (95% CI, 1.89-11.11), compared with 0.98 (95% CI, 0.47-2.05) for LN metastasis. MTDs, but not LN metastasis, in midgut NETs are a strong predictor for hepatic metastasis and are associated with poor DSS.
*Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN †Department of Pathology, University of Rochester Medical Center, Rochester, NY ‡Department of Surgery, Rocky Mountain Cancer Centers, Denver, CO.
Cynthia R
CR
Fata
Raul S
RS
Gonzalez
Eric
E
Liu
Justin M
JM
Cates
Chanjuan
C
Shi
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007414:Intestinal Neoplasms / Q000401:mortality / Q000473:pathology*; D007421:Intestine, Small / Q000473:pathology; D053208:Kaplan-Meier Estimate; D008113:Liver Neoplasms / Q000401:mortality / Q000556:secondary; D008207:Lymphatic Metastasis / Q000473:pathology; D008297:Male; D008643:Mesentery / Q000473:pathology*; D008875:Middle Aged; D018358:Neuroendocrine Tumors / Q000401:mortality / Q000473:pathology*; D011379:Prognosis; D016016:Proportional Hazards Models; D055815:Young Adult
Hum Pathol. 2009 Sep;40(9):1262-8
19368957
J Clin Oncol. 2008 Jun 20;26(18):3063-72
18565894
Mod Pathol. 2007 Aug;20(8):843-55
17491597
Am J Gastroenterol. 2007 Jul;102(7):1464-73
17391319
Cancer Causes Control. 2005 Sep;16(7):781-7
16132788
Neuroendocrinology. 2012;96(1):32-40
22205326
Ann Oncol. 2013 Dec;24(12):3040-4
24050954
J Clin Oncol. 2013 Feb 1;31(4):420-5
23248248
J Cancer. 2012;3:292-302
22773933
Cancer. 2003 Feb 15;97(4):934-59
12569593
Mod Pathol. 2014 Sep;27(9):1288-95
24457461
Cancer. 2008 Jan 1;112(1):50-4
18008365
Endocrinol Metab Clin North Am. 2011 Mar;40(1):1-18, vii
21349409
Hum Pathol. 2012 Apr;43(4):489-95
21937080
Am J Clin Pathol. 2010 Mar;133(3):388-94
20154277
Endocr Relat Cancer. 2009 Sep;16(3):885-94
19458024
Am J Clin Pathol. 2015 Mar;143(3):398-404
25696798
Endocr Pathol. 2014 Jun;25(2):165-70
24699926
Cancer. 2008 Nov 15;113(10):2655-64
18853416
Best Pract Res Clin Gastroenterol. 2012 Dec;26(6):691-703
23582913
Eur J Gastroenterol Hepatol. 2013 Feb;25(2):232-8
23108416